Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts (original) (raw)

• Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC . The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42: 1564–1573.
  Article CAS Google Scholar
• Hazlehurst LA, Landowski TH, Dalton WS . Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003; 22: 7396–7402.
  Article CAS Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.
  Article CAS Google Scholar
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
  Article CAS Google Scholar
• Bataille R, Jourdan M, Zhang XG, Klein B . Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008–2011.
  Article CAS Google Scholar
• Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104–1112.
  CAS Google Scholar
• Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA . A crosstalk between Myeloma cells and marrow stromal cells stimulates production of DKK1 and IL-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986–991.
  Article CAS Google Scholar
• Podar K, Anderson KC . The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383–1395.
  Article CAS Google Scholar
• Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R . A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000; 109: 661–664.
  Article CAS Google Scholar
• Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Mathews S, Dong RP et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. Invest New Drugs 2006; 24: 529–535.
  CAS Google Scholar
• Dillon SR, Gross JA, Ansell SM, Novak AJ . An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235–246.
  Article CAS Google Scholar
• Jelinek DF, Darce JR . Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun 2005; 8: 266–288.
  Article CAS Google Scholar
• Shivakumar L, Ansell S . Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 2006; 7: 106–108.
  Article Google Scholar
• Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148–3157.
  Article CAS Google Scholar
• Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689–694.
  Article CAS Google Scholar
• Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675–6682.
  Article CAS Google Scholar
• Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021–1030.
  Article CAS Google Scholar
• Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313–1315.
  Article CAS Google Scholar
• Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006; 203: 1859–1865.
  Article CAS Google Scholar
• Yaccoby S, Barlogie B, Epstein J . Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908–2913.
  CAS Google Scholar
• Yaccoby S, Epstein J . The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576–3582.
  CAS Google Scholar
• Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004; 64: 2016–2023.
  Article CAS Google Scholar
• Yaccoby S . The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005; 11: 7599–7606.
  Article CAS Google Scholar
• Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J . Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278–290.
  Article Google Scholar
• Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J . Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002; 100: 4162–4168.
  Article CAS Google Scholar
• Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006; 91: 192–199.
  CAS Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757.
  Article CAS Google Scholar
• Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028.
  Article CAS Google Scholar
• Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.
  Article CAS Google Scholar
• Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr . Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–2111.
  Article CAS Google Scholar
• Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby Y . Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol 2006; 133: 83–92.
  Article CAS Google Scholar
• Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007; 109: 4470–4477.
  Article CAS Google Scholar
• Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148–3157.
  Article CAS Google Scholar
• Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201: 1375–1383.
  Article CAS Google Scholar
• Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12: 637–648.
  Article CAS Google Scholar
• Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A . Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005; 96: 897–905.
  Article CAS Google Scholar
• Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100: 610–617.
  Article CAS Google Scholar
• Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007; 110: 2041–2048.
  Article CAS Google Scholar
• Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, Nilson A et al. Selective activation of TACI by syndecan-2. Blood 2006; 107: 3235–3242.
  Article CAS Google Scholar
• Roodman GD . Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655–1664.
  Article CAS Google Scholar
• Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482–492.
  Article CAS Google Scholar
• Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484–2491.
  Article CAS Google Scholar